Breast Cancer Study

Study Name:

A phase 3 randomized, open-label study of Palazestrant (OP-1250) monotherapy vs standard of care for the treatment of ER+, HER2– advanced or metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy (OPERA-01)

Eligibility:

  1. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast with evidence of locally advanced or metastatic breast cancer that is not amenable to curative therapy.

  2. ER+, HER2-

Treatment 1:

Palazestrant (OP-1250)

Treatment 2:

Standard endocrine therapy

Personal Data Disclosure Disclaimer: We may collect, use, and disclose your personal data in accordance with the Personal Data (Privacy) Ordinance. Your information will be handled with care and only used for the purposes specified at the time of collection.